Biogen Idec submitted an investigational new drug (IND) application

06.04.2011

Biogen Idec submitted an investigational new drug (IND) application to the FDA to evaluate its anti-beta-amyloid antibody BART (BIIB037) as a potential new treatment for Alzheimer's disease. BIIB037 binds to parenchymal amyloid and clears parenchymal plaques in transgenic mice without causing microbleeds.

News overview

This website uses cookies, with the aim of ensuring that you have the best possible online experience. In using our website, you are giving your consent to the terms and conditions of our Privacy policy

Your web browser is out of date

Update your browser for more security, speed and the best experience.

Update my browser Continue